LifeSplice Pharma is pleased to announce the publication of the article “AMPA GluA1-flip targeted oligonucleotide therapy reduces neonatal seizures and hyperexcitability” in the PLOS One Journal. The paper was authored by LifeSplice’s own Dr. Nicole Lykens and Dr. David Coughlin with co-authorship from Dr. Melanie K. Tallent and Dr. Gordon J. Lutz. Click here to view the article in its entirety.